[
  {
    "ts": null,
    "headline": "Is Merck & Co. (MRK) the Best Depressed Stock to Invest in Now?",
    "summary": "We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best depressed stocks to invest in now. The US stocks ended 2024 with a healthy Q4, as the equity markets were primarily […]",
    "url": "https://finnhub.io/api/news?id=50e6e3cc9aa4fae7fe5944f620fc8ee38bf9a803a7ede41c5c9184d8604b7ec2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738008464,
      "headline": "Is Merck & Co. (MRK) the Best Depressed Stock to Invest in Now?",
      "id": 132505714,
      "image": "https://s.yimg.com/ny/api/res/1.2/krpa0cobX2AdeFb7DJ59pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best depressed stocks to invest in now. The US stocks ended 2024 with a healthy Q4, as the equity markets were primarily […]",
      "url": "https://finnhub.io/api/news?id=50e6e3cc9aa4fae7fe5944f620fc8ee38bf9a803a7ede41c5c9184d8604b7ec2"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "summary": "Merck & Co. Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=a113276a0c057aad2830897402a91a7bafa7dba6cfb476cc83389f0b2c2f4e61",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737995580,
      "headline": "Merck & Co. Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "id": 132521886,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=a113276a0c057aad2830897402a91a7bafa7dba6cfb476cc83389f0b2c2f4e61"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)",
    "summary": "RAHWAY, N.J., January 27, 2025--FDA Accepts for Priority Review Merck's Application for WELIREG for Treatment of Advanced PPGL",
    "url": "https://finnhub.io/api/news?id=70e0a566bf57cd34037524c93e35257690f41424361ccb0d6b2c1cae1ee7e5ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737978300,
      "headline": "FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)",
      "id": 132505715,
      "image": "https://media.zenfs.com/en/business-wire.com/c3db75e583e8503c7f95cb7880bfb9ad",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., January 27, 2025--FDA Accepts for Priority Review Merck's Application for WELIREG for Treatment of Advanced PPGL",
      "url": "https://finnhub.io/api/news?id=70e0a566bf57cd34037524c93e35257690f41424361ccb0d6b2c1cae1ee7e5ae"
    }
  },
  {
    "ts": null,
    "headline": "Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA plus LENVIMA in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma",
    "summary": "RAHWAY, NUTLEY - Merck , known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA , Merck's anti-PD-1 therapy, plus...",
    "url": "https://finnhub.io/api/news?id=6524ecf03786862e61889a0d8b642a5ac3cba4b3915df79ee641f8dfc6f94e20",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737975925,
      "headline": "Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA plus LENVIMA in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma",
      "id": 132479965,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY, NUTLEY - Merck , known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA , Merck's anti-PD-1 therapy, plus...",
      "url": "https://finnhub.io/api/news?id=6524ecf03786862e61889a0d8b642a5ac3cba4b3915df79ee641f8dfc6f94e20"
    }
  },
  {
    "ts": null,
    "headline": "Merck: priority review for Welireg in the USA",
    "summary": "Merck announced Monday that the U.S. Food and Drug Administration has granted priority review to its Welireg tablet for the treatment of advanced pheochromocytomas and...",
    "url": "https://finnhub.io/api/news?id=d638c93e7b4f53f92dc7e17602a1fcaa8ac1db3e7c0475b85e5230c76c29d634",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737966494,
      "headline": "Merck: priority review for Welireg in the USA",
      "id": 132479100,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced Monday that the U.S. Food and Drug Administration has granted priority review to its Welireg tablet for the treatment of advanced pheochromocytomas and...",
      "url": "https://finnhub.io/api/news?id=d638c93e7b4f53f92dc7e17602a1fcaa8ac1db3e7c0475b85e5230c76c29d634"
    }
  },
  {
    "ts": null,
    "headline": "Merck Gets FDA Priority Review of Welireg in Rare Adrenal Tumors",
    "summary": "By Colin Kellaher Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that...",
    "url": "https://finnhub.io/api/news?id=3b82b148a6678cd8895af07143e1fa1bce259b966517e5068c630e8e3baad8b7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737962775,
      "headline": "Merck Gets FDA Priority Review of Welireg in Rare Adrenal Tumors",
      "id": 132478773,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that...",
      "url": "https://finnhub.io/api/news?id=3b82b148a6678cd8895af07143e1fa1bce259b966517e5068c630e8e3baad8b7"
    }
  }
]